TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients
Brief Summary: This randomized multicentric clinical trial assesses the effectiveness of 24 hour phone line on the rate of suicide attempts and self-injurious behaviors in borderline patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2
B: Arm Label: brief intervention to prevent suicide attempt; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention to prevent suicide attempt | Arm Label: standard of care; Type: OTHER; Interventions: Behavioral: Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Brief intervention to prevent suicide attempt; Assigned to Arm(s): brief intervention to prevent suicide attempt | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual; Assigned to Arm(s): standard of care
C: Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Teachable Moment Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Teachable Moment Brief Intervention | Intervention Type: BEHAVIORAL; Name: Teachable Moment Brief Intervention; Assigned to Arm(s): Teachable Moment Brief Intervention
D: Arm Label: Immediate Functional Imagery Training (FIT); Type: EXPERIMENTAL; Interventions: Behavioral: Functional Imagery Training (FIT) | Arm Label: Delayed Functional Imagery Training (FIT); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Functional Imagery Training (FIT); Assigned to Arm(s): Immediate Functional Imagery Training (FIT)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients
Brief Summary: This randomized multicentric clinical trial assesses the effectiveness of 24 hour phone line on the rate of suicide attempts and self-injurious behaviors in borderline patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2
B: Arm Label: Commitment; Type: EXPERIMENTAL; Interventions: Behavioral: DBT Skills Training | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT Skills Training | Intervention Type: BEHAVIORAL; Name: DBT Skills Training; Assigned to Arm(s): Commitment, Psychoeducation
C: Arm Label: Internet-based ERITA-DK; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK) | Arm Label: Treatment as Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK) | Intervention Type: BEHAVIORAL; Name: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK); Assigned to Arm(s): Internet-based ERITA-DK, Treatment as Usual (TAU)
D: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients
Brief Summary: This randomized multicentric clinical trial assesses the effectiveness of 24 hour phone line on the rate of suicide attempts and self-injurious behaviors in borderline patients.


Options:
A: Arm Label: short-term dynamic therapy; Type: EXPERIMENTAL; Interventions: Behavioral: short-term dynamic therapy | Arm Label: long-term dynamic therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: long-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: short-term dynamic therapy; Assigned to Arm(s): short-term dynamic therapy | Intervention Type: BEHAVIORAL; Name: long-term dynamic therapy; Assigned to Arm(s): long-term dynamic therapy
B: Arm Label: dynamic deconstructive psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psychodynamic Therapy | Arm Label: optimized community care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Optimized Community Care | Intervention Type: BEHAVIORAL; Name: Psychodynamic Therapy; Assigned to Arm(s): dynamic deconstructive psychotherapy | Intervention Type: BEHAVIORAL; Name: Optimized Community Care; Assigned to Arm(s): optimized community care
C: Arm Label: Treatment; Type: N/A; Interventions: Behavioral: Dialectical Behavioural Therapy (DBT) | Arm Label: Waitlist; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical Behavioural Therapy (DBT); Assigned to Arm(s): Treatment
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients
Brief Summary: This randomized multicentric clinical trial assesses the effectiveness of 24 hour phone line on the rate of suicide attempts and self-injurious behaviors in borderline patients.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 2; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 3; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 4; Type: OTHER; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief PTSD treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Brief PTSD treatment; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2
D: Arm Label: Priovi; Type: EXPERIMENTAL; Interventions: Behavioral: Priovi, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Priovi; Assigned to Arm(s): Priovi | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Priovi

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent an
Brief Summary: This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.


Options:
A: Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X
B: Arm Label: FF/VI; Type: EXPERIMENTAL; Interventions: Drug: FF/VI | Arm Label: Existing Maintenance Therapy; Type: OTHER; Interventions: Other: Existing Maintenance Therapy | Intervention Type: DRUG; Name: FF/VI; Assigned to Arm(s): FF/VI | Intervention Type: OTHER; Name: Existing Maintenance Therapy; Assigned to Arm(s): Existing Maintenance Therapy
C: Arm Label: LABA; Type: EXPERIMENTAL; Interventions: Drug: GW642444 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): LABA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: C/E/A/B/D; Type: EXPERIMENTAL; Interventions: Drug: Dose 2 QD | Arm Label: D/C/E/A/B; Type: EXPERIMENTAL; Interventions: Drug: Dose 3 QD | Arm Label: A/B/C/D/E; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: B/A/D/E/C; Type: EXPERIMENTAL; Interventions: Drug: Dose 1 BD | Arm Label: E/D/B/C/A; Type: EXPERIMENTAL; Interventions: Drug: Dose 4 QD | Intervention Type: DRUG; Name: Dose 4 QD; Assigned to Arm(s): E/D/B/C/A | Intervention Type: DRUG; Name: Dose 3 QD; Assigned to Arm(s): D/C/E/A/B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A/B/C/D/E | Intervention Type: DRUG; Name: Dose 2 QD; Assigned to Arm(s): C/E/A/B/D | Intervention Type: DRUG; Name: Dose 1 BD; Assigned to Arm(s): B/A/D/E/C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients
Brief Summary: The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.


Options:
A: Arm Label: VI-0521 Top; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: VI-0521 Mid; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: VI-0521 | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Top | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Mid | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): Placebo
B: Arm Label: Lorcaserin 10 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg once daily (QD) | Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg twice a day (BID) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo | Intervention Type: DRUG; Name: Lorcaserin 10 mg once daily (QD); Assigned to Arm(s): Lorcaserin 10 mg QD | Intervention Type: DRUG; Name: Lorcaserin 10 mg twice a day (BID); Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
C: Arm Label: Lorcaserin hydrochloride (HCL)10 mg; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lorcaserin hydrochloride; Assigned to Arm(s): Lorcaserin hydrochloride (HCL)10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Allogeneic Hematopoietic Cell Transplantation With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
Brief Summary: The present project aims at comparing two nonmyeloablative regimens currently used in 2 major HCT centers in the US for patients with HLA-matched related or unrelated donor: the one from the Seattle group consisting of 2 Gy TBI with fludarabine (90 mg/m²) versus the one from the Stanford group combining 8 Gy TLI with ATG.


Options:
A: Arm Label: routine prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: anti thymoglobulin | Arm Label: ATG prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: anti thymoglobulin | Intervention Type: DRUG; Name: anti thymoglobulin; Assigned to Arm(s): ATG prophylaxis, routine prophylaxis
B: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Best Available Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extracorporeal photopheresis (ECP), Drug: Low-dose methotrexate (MTX), Drug: Mycophenolate mofetil (MMF), Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Drug: Infliximab, Drug: Rituximab, Drug: Pentostatin, Drug: Imatinib, Drug: Ibrutinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib | Intervention Type: DRUG; Name: Extracorporeal photopheresis (ECP); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Low-dose methotrexate (MTX); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Imatinib; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Best Available Therapy
C: Arm Label: TBI + fludarabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conditioning regimen: TBI + Fludarabine | Arm Label: TLI + ATG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conditioning regimen:TLI (8 Gy) + ATG | Intervention Type: DRUG; Name: Conditioning regimen: TBI + Fludarabine; Assigned to Arm(s): TBI + fludarabine | Intervention Type: DRUG; Name: Conditioning regimen:TLI (8 Gy) + ATG; Assigned to Arm(s): TLI + ATG
D: Arm Label: ATG-F; Type: EXPERIMENTAL; Interventions: Drug: ATG-Fresenius S | Arm Label: non-ATG-F; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ATG-Fresenius S; Assigned to Arm(s): ATG-F

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock
Brief Summary: We are performing a prospective, randomized, controlled trial of dopamine versus norepinephrine for septic shock. The trial will enroll patients with suspected or documented site of infection and having 2 out of the three SIRS criteria. Patients will also be receiving standard of care, early-goal directed therapy including but not limited to fluid resuscitation, appropriate and early antibiotics, source control and evaluation for drotrecogin alpha where deemed appropriate, while being supported for septic shock.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vasopressin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): 3
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Early Goal Directed Therapy (EGDT) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Protocolized Standard Care (PSC) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual Care (UC) | Intervention Type: PROCEDURE; Name: Early Goal Directed Therapy (EGDT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Protocolized Standard Care (PSC); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Usual Care (UC); Assigned to Arm(s): 3
C: Arm Label: Dopamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dopamine | Arm Label: Norepinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Dopamine; Assigned to Arm(s): Dopamine | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): Norepinephrine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: norepinephrine and dobutamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epinephrine plus placebo of dobutamine | Intervention Type: DRUG; Name: norepinephrine and dobutamine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: epinephrine plus placebo of dobutamine; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine Administered Intradermally vs Full Doses of Inactivated Poliomyelitis Vaccine Administered Intramuscularly in Healthy Philippines Infants
Brief Summary: The present study intends to investigate the use of fractional doses of sanofi pasteur's IMOVAX Polio injected intradermally. The primary objective will be to demonstrate the non-inferiority of fractional doses of IMOVAX Polio administered intradermally versus full doses of IMOVAX Polio administered intramuscularly, in terms of seroprotection rates (polio types 1, 2 and 3) one month after the three-dose primary vaccination administered at 6-10-14 weeks of age.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM, Biological: Infanrix+Hib | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Infanrix+Hib | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Infanrix+Hib; Assigned to Arm(s): Group A, Group B
B: Arm Label: IPV IM (Visit 1); Type: EXPERIMENTAL; Interventions: Drug: IPV IM Needle | Arm Label: IPV IM (Visit 2); Type: EXPERIMENTAL; Interventions: Drug: IPV IM Needle | Arm Label: IPV IM (Device - Visit 2); Type: EXPERIMENTAL; Interventions: Drug: IPV IM Device | Arm Label: IPV IM and MR (Visit1); Type: EXPERIMENTAL; Interventions: Drug: IPV IM Needle | Arm Label: IPV IM and YF (Visit 1); Type: EXPERIMENTAL; Interventions: Drug: IPV IM Needle | Arm Label: IPV ID (Visit 2); Type: EXPERIMENTAL; Interventions: Drug: IPV ID Needle | Arm Label: IPV IM and MR and YF (Visit 1); Type: EXPERIMENTAL; Interventions: Drug: IPV IM Needle | Arm Label: IPV (ID Device Visit 2); Type: EXPERIMENTAL; Interventions: Drug: IPV ID Device | Intervention Type: DRUG; Name: IPV IM Needle; Assigned to Arm(s): IPV IM (Visit 1), IPV IM (Visit 2), IPV IM and MR (Visit1), IPV IM and MR and YF (Visit 1), IPV IM and YF (Visit 1) | Intervention Type: DRUG; Name: IPV ID Needle; Assigned to Arm(s): IPV ID (Visit 2) | Intervention Type: DRUG; Name: IPV IM Device; Assigned to Arm(s): IPV IM (Device - Visit 2) | Intervention Type: DRUG; Name: IPV ID Device; Assigned to Arm(s): IPV (ID Device Visit 2)
C: Arm Label: POLIORIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): POLIORIX GROUP
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Youth Suicide in Primary Care: A Family Model
Brief Summary: The purpose of the study is to test the efficacy of a brief family therapy (Attachment-Based Family Therapy) for youth presenting in primary care with suicidal ideation and depressed mood.


Options:
A: Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3
C: Arm Label: Youth-Nominated Support Team; Type: EXPERIMENTAL; Interventions: Behavioral: Youth-Nominated Support Team | Arm Label: Enhanced Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Youth-Nominated Support Team; Assigned to Arm(s): Youth-Nominated Support Team
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Attachment-Based Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Attachment-Based Family Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interest in Biventricular Epicardial Pacing Post Cardiac Surgery in Patients With Left Ventricular Ejection Fractions Less Than 45%
Brief Summary: Patients with reduced left ventricular function are at an increased perioperative risk and often need prolonged postoperative treatment on intensive care units. A significant portion of these patients require postoperative pacing. Right ventricular pacing has been shown to be hemodynamically deleterious The aim of this study is to determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF≤ 45%), is hemodynamically favourable.


Options:
A: Intervention Type: OTHER; Name: Biventricular pacing post cardiac surgery; Assigned to Arm(s): N/A
B: Arm Label: Proton pump inhibitor (PPI); Type: EXPERIMENTAL; Interventions: Drug: Pantoprazole | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (0.9%) | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Proton pump inhibitor (PPI) | Intervention Type: OTHER; Name: Saline (0.9%); Assigned to Arm(s): Normal saline
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole 20 mg daily | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: famotidine 40 mg daily | Intervention Type: DRUG; Name: esomeprazole 20 mg daily; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: famotidine 40 mg daily; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Esomeprazole Sodium; Assigned to Arm(s): N/A

Answer: A